Skip to main content

CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 and BMS-986288, anti-CTLA-4 Probody therapeutics generated with CytomX’s novel Probody® technology platform. The electronic poster #4551 titled “Preclinical characterization of novel anti-CTLA-4 prodrug antibodies with an enhanced therapeutic index” was presented as part of the Therapeutic Antibodies 3 Session at the American Association of Cancer Research’s (AACR) 2020 Virtual Annual Meeting II.
BMS-986249 is a Probody version of the anti-CTLA-4 antibody ipilimumab (Yervoy®). In February 2020, Bristol Myers Squibb treated the first patient in a Part 2a randomized cohort expansion in an ongoing Phase 1/2a trial of BMS-986249 in combination with Opdivo® (nivolumab) in patients with metastatic melanoma. Additional information is available at ClinicalTrials.gov using the Identifier NCT03369223. BMS-986288 is a Probody of a nonfucosylated version of ipilimumab (anti-CTLA-4 NF). In September 2019, Bristol Myers Squibb initiated the dose escalation phase of a Phase 1/2a clinical trial of BMS-986288 administered as monotherapy and in combination with nivolumab in patients with selected advanced solid tumors. Additional information is available at ClinicalTrials.gov using the Identifier NCT03994601. These Probody programs, designed to optimize the therapeutic index of CTLA-4-directed therapy, arose from the companies’ 2014 worldwide oncology license and collaboration agreement.“This important work within our Bristol Myers Squibb alliance is aimed at broadening the utility of this foundational immunotherapeutic approach to the treatment of cancer,” said Sean McCarthy D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. “We look forward to seeing the full potential of these programs as they continue to advance in the clinic.”About CytomX Therapeutics

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.